Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Eyes DPP-4, GLP-1 Data From Diabetes Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

BMS to release first Phase III data on saxagliptin as monotherapy.
Advertisement

Related Content

Takeda’s Alogliptin Strategy: Treatment Options
Takeda’s Alogliptin Strategy: Treatment Options
Liraglutide Up For Approval In U.S. And Europe
Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales
Bristol Eyes 2008 NDA For DPP-4 Inhibitor Saxagliptin
Bristol Eyes 2008 NDA For DPP-4 Inhibitor Saxagliptin

Topics

Advertisement
UsernamePublicRestriction

Register

PS068028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel